Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Jun 14. doi: 10.1001/jamaoncol.2018.1701. [Epub ahead of print]


In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma.

Bush KT, Boichard A, Tsigelny IF.

Anticancer Res. 2018 Apr;38(4):1967-1977.


Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Oncoimmunology. 2017 Dec 22;7(3):e1404217. doi: 10.1080/2162402X.2017.1404217. eCollection 2018.


BRAF mutation as a novel driver of eosinophilic cystitis.

Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R.

Cancer Biol Ther. 2017 Sep 2;18(9):655-659. doi: 10.1080/15384047.2017.1360449. Epub 2017 Aug 22.


High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.

Boichard A, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2017 Jan 31;6(3):e1284719. doi: 10.1080/2162402X.2017.1284719. eCollection 2017.


Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.

Rodriguez C, Suciu V, Poterie A, Lacroix L, Miran I, Boichard A, Delaloge S, Deneuve J, Azoulay S, Mathieu MC, Valent A, Michiels S, Arnedos M, Vielh P.

Mol Oncol. 2016 Nov;10(9):1430-1436. doi: 10.1016/j.molonc.2016.07.009. Epub 2016 Aug 5.


RET mutation and increased angiogenesis in medullary thyroid carcinomas.

Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C.

Endocr Relat Cancer. 2016 Aug;23(8):665-76. doi: 10.1530/ERC-16-0132. Epub 2016 Jul 8.


Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L.

Clin Cancer Res. 2016 Jun 15;22(12):2960-8. doi: 10.1158/1078-0432.CCR-15-2470. Epub 2016 Jan 12.


Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.

Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S.

Mol Cell Endocrinol. 2014 Jul 5;392(1-2):8-13. doi: 10.1016/j.mce.2014.04.016. Epub 2014 May 9.


Genomes in the clinic: the Gustave Roussy Cancer Center experience.

Lacroix L, Boichard A, André F, Soria JC.

Curr Opin Genet Dev. 2014 Feb;24:99-106. doi: 10.1016/j.gde.2013.11.013. Epub 2014 Feb 26. Review.


Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G.

Endocrine. 2014 Nov;47(2):528-36. doi: 10.1007/s12020-014-0204-3. Epub 2014 Feb 26.


Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L.

J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5. doi: 10.1210/jc.2012-2092. Epub 2012 Aug 3.


Two silent substitutions in the PDHA1 gene cause exon 5 skipping by disruption of a putative exonic splicing enhancer.

Boichard A, Venet L, Naas T, Boutron A, Chevret L, de Baulny HO, De Lonlay P, Legrand A, Nordman P, Brivet M.

Mol Genet Metab. 2008 Mar;93(3):323-30. Epub 2007 Nov 26.


Supplemental Content

Loading ...
Support Center